tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

REGN Stock Latest News

Regeneron’s New Study on Anticoagulant Alternatives: A Potential Game Changer?
Company AnnouncementsRegeneron’s New Study on Anticoagulant Alternatives: A Potential Game Changer?
6h ago
REGN
Regeneron’s Promising Phase 3 Trial for Follicular Lymphoma: A Potential Game-Changer?
PremiumCompany Announcements
Regeneron’s Promising Phase 3 Trial for Follicular Lymphoma: A Potential Game-Changer?
6h ago
REGN
Regeneron and Sanofi’s Dupilumab Study: A Potential Breakthrough in Eosinophilic Gastritis Treatment
PremiumCompany Announcements
Regeneron and Sanofi’s Dupilumab Study: A Potential Breakthrough in Eosinophilic Gastritis Treatment
6h ago
SNY
REGN
Regeneron’s Phase 3 Study on REGN7508: A Potential Game-Changer in VTE Prevention
PremiumCompany Announcements
Regeneron’s Phase 3 Study on REGN7508: A Potential Game-Changer in VTE Prevention
6h ago
REGN
Regeneron and Sanofi’s AROMA Study: Long-Term Insights on DUPIXENT® for CRSwNP
PremiumCompany Announcements
Regeneron and Sanofi’s AROMA Study: Long-Term Insights on DUPIXENT® for CRSwNP
7h ago
SNY
REGN
QQQ ETF News, 7/18/2025
PremiumMarket NewsQQQ ETF News, 7/18/2025
12h ago
ON
AMD
Regeneron and Sanofi’s Phase 3 Study on Itepekimab: A Potential Game-Changer for Chronic Rhinosinusitis
Premium
Company Announcements
Regeneron and Sanofi’s Phase 3 Study on Itepekimab: A Potential Game-Changer for Chronic Rhinosinusitis
1d ago
SNY
REGN
Regeneron and Sanofi’s Phase 3 Study on Itepekimab: A Potential Game Changer for Chronic Rhinosinusitis
Premium
Company Announcements
Regeneron and Sanofi’s Phase 3 Study on Itepekimab: A Potential Game Changer for Chronic Rhinosinusitis
1d ago
SNY
REGN
Regeneron and Intellia’s Gene Therapy Study for Hemophilia B: A Market Game-Changer?
PremiumCompany Announcements
Regeneron and Intellia’s Gene Therapy Study for Hemophilia B: A Market Game-Changer?
1d ago
NTLA
REGN
Regeneron’s Long-Term Melanoma Study: Key Insights for Investors
PremiumCompany Announcements
Regeneron’s Long-Term Melanoma Study: Key Insights for Investors
1d ago
REGN
Regeneron’s Promising Study on Odronextamab for B-cell Non-Hodgkin Lymphoma
PremiumCompany Announcements
Regeneron’s Promising Study on Odronextamab for B-cell Non-Hodgkin Lymphoma
1d ago
REGN
Regeneron’s Promising Obesity Treatment Study: A Potential Game-Changer?
PremiumCompany Announcements
Regeneron’s Promising Obesity Treatment Study: A Potential Game-Changer?
1d ago
REGN
Avidity, Phathom mentioned as potential takeout targets at Needham
PremiumThe FlyAvidity, Phathom mentioned as potential takeout targets at Needham
1d ago
BMY
NVO
QQQ ETF News, 7/17/2025
Premium
Market News
QQQ ETF News, 7/17/2025
1d ago
ON
AMD
Regeneron Advances Melanoma Treatment with New Phase 2 Trial
Premium
Company Announcements
Regeneron Advances Melanoma Treatment with New Phase 2 Trial
2d ago
REGN
Regeneron’s Latest Study on Gastrointestinal Blood Loss: Key Insights for Investors
PremiumCompany Announcements
Regeneron’s Latest Study on Gastrointestinal Blood Loss: Key Insights for Investors
2d ago
REGN
Regeneron’s Innovative Approach in Follicular Lymphoma Treatment: A New Phase 3 Trial
PremiumCompany Announcements
Regeneron’s Innovative Approach in Follicular Lymphoma Treatment: A New Phase 3 Trial
2d ago
REGN
Regeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Eosinophilic Gastritis
PremiumCompany Announcements
Regeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Eosinophilic Gastritis
2d ago
SNY
REGN
QQQ ETF News, 7/16/2025
PremiumMarket News
QQQ ETF News, 7/16/2025
2d ago
AMD
APP
Regeneron and Sanofi’s Phase 3 Study on Itepekimab: A Potential Game-Changer for Chronic Rhinosinusitis Treatment
PremiumCompany AnnouncementsRegeneron and Sanofi’s Phase 3 Study on Itepekimab: A Potential Game-Changer for Chronic Rhinosinusitis Treatment
3d ago
SNY
REGN
Regeneron and Sanofi’s Phase 3 Study on Itepekimab: A Potential Game-Changer for CRSwNP
Premium
Company Announcements
Regeneron and Sanofi’s Phase 3 Study on Itepekimab: A Potential Game-Changer for CRSwNP
3d ago
SNY
REGN
Regeneron and Intellia’s Gene Therapy Study: A Potential Game-Changer for Hemophilia B
Premium
Company Announcements
Regeneron and Intellia’s Gene Therapy Study: A Potential Game-Changer for Hemophilia B
3d ago
NTLA
REGN

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >